| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685443 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(1 year, 9 months from now) | |
| US8685444 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(1 year, 9 months from now) | |
| US8846104 | ALPHARMA PHARMS | Pharmaceutical compositions for the deterrence and/or prevention of abuse |
Jun, 2027
(3 years from now) | |
| US8877247 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(3 years from now) | |
| US7682633 | ALPHARMA PHARMS | Pharmaceutical composition |
Jun, 2027
(3 years from now) | |
| US7682634 | ALPHARMA PHARMS | Pharmaceutical compositions |
Jun, 2027
(3 years from now) | |
| US8158156 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(3 years from now) | |
| US7815934 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Dec, 2027
(4 years from now) | |
| US8623418 | ALPHARMA PHARMS | Pharmaceutical composition |
Nov, 2029
(6 years from now) | |
Embeda is owned by Alpharma Pharms.
Embeda contains Morphine Sulfate; Naltrexone Hydrochloride.
Embeda has a total of 9 drug patents out of which 0 drug patents have expired.
Embeda was authorised for market use on 13 August, 2009.
Embeda is available in capsule, extended release;oral dosage forms.
Embeda can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatement by orally administering an intact composition as claimed., treatment of moderate to severe chronic pain by administering an intact composition as claimed, management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed.
The generics of Embeda are possible to be released after 07 November, 2029.
Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed; Management of pain severe enough t...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
EMBEDA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic